Milan - Delayed Quote EUR

REGENERON PHARMACEUTICALS (1REGN.MI)

687.00

-29.00

(-4.05%)

At close: January 2 at 10:13:08 AM GMT+1

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of R

GlobeNewswire 4 days ago

REGN
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years

The last three months have been tough on Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders, who have seen...

Simply Wall St. 11 days ago

REGN
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regene

GlobeNewswire 23 days ago

REGN
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will

GlobeNewswire 25 days ago

REGN
Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial

Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.

The Wall Street Journal 25 days ago

REGN
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endp

GlobeNewswire 25 days ago

REGN
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company’s leadership in adopting responsible practices that drive business resilience and improve our world. The DJSI World Index is a leading benchmark for corpo

GlobeNewswire 26 days ago

REGN
Regeneron reinstated with an Underperform at BofA

BofA reinstated coverage of Regeneron (REGN) with an Underperform rating and $565 price target The firm calls Regeneron a “high-quality company,” with “lots to like generally,” but thinks Eylea, its lead franchise, erodes faster and harder than consensus. Despite a pullback in shares, the premium remains “too big,” especially given the firm’s below-consensus 2025 EPS view, the analyst added. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

TipRanks last month

REGN
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial Primary analysis from an expansion cohort of the ELM-1 trial highlighted continued efficacy and durability in diffuse large B-cell lymphoma patients whose disease had progressed after CAR-T therapy First results from the ELM-2 trial in marginal zone lymphoma demonstr

GlobeNewswire last month

REGN
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab Five patients receiving ravulizumab did not achieve meaningful LDH control compared to one patient receiving poze-cemdi; after switching to the combination, four of the five previously treated with ravulizumab achieved LDH control A separat

GlobeNewswire last month

REGN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...

Simply Wall St. last month

REGN
Galderma Bets on Skin Drug to Turn Around Pharma Business

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.

The Wall Street Journal last month

LLY

ABBV

REGN
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy

In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...

Simply Wall St. last month

REGN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Investor's Business Daily last month

NTLA

BBIO

PFE
Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 15% CAGR over the last five years

Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might understandably be very concerned that the share...

Simply Wall St. last month

REGN
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administ

GlobeNewswire last month

SNY

SNYNF

REGN
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first-line follicular lymphoma showcase compelling monotherapy potential and progress in the confirmatory trial Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results

GlobeNewswire last month

REGN
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on Tuesday, November 19, 2024 • Piper Sandler 36th Annual Healthcare Conference at 9:30 a.m. ET on Thursday, December 5, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replay

GlobeNewswire last month

REGN
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Simply Wall St. 2 months ago

REGN
Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With the shares off about 30% since the surprising news of an at-risk biosimilar launch, the firm wanted to quantify the potential risks to EYLEA’s franchise in the near term. Using other biosimilar launches as a guide, Oppenheimer believes the selloff is somewhat overdone-and has updated our model to assume about 30% cannibalization to EYLEA sales within five years

TipRanks 2 months ago

REGN

Performance Overview

Return	1REGN.MI	S&P 500
YTD	+0.44%	-1.35%
1-Year	-16.07%	+22.51%
3-Year	-5.89%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

REGENERON PHARMACEUTICALS (1REGN.MI)

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

Regeneron reinstated with an Underperform at BofA

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Galderma Bets on Skin Drug to Turn Around Pharma Business

Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 15% CAGR over the last five years

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Regeneron Announces Investor Conference Presentations

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

Performance Overview